Every 8-K that LENSAR, Inc. (LNSR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LNSR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNSR filings page.
LENSAR, Inc. reported strong results for the quarter ended June 30, 2026, with total revenue of $16.5 million, up 18% from the prior-year quarter. Recurring revenue reached $13.7 million, a 20% increase, and accounted for 83% of total revenue.
Procedure revenue rose 23% to $10.2 million on procedure volume of 58,682, up 13% year over year. The total laser installed base grew to 445 systems, including 215 ALLY Robotic Cataract Laser Systems, with 10 new ALLY placements in the quarter and a backlog of 13 systems.
The company generated net income of $3.5 million versus a $1.8 million loss a year earlier, and delivered its strongest Adjusted EBITDA to date at $3.6 million, compared with a $0.3 million loss. Management cited higher revenue, lower operating expenses, and a $1.1 million tariff refund as key drivers, while noting reduced non-cash income from warrant liability revaluation. Cash, cash equivalents and investments totaled $13.6 million at June 30, 2026, down from $18.0 million at December 31, 2025.
LENSAR, Inc. reported the results of its 2026 annual stockholders meeting. As of the June 10, 2026 record date, there were 12,281,581 common shares and 20,000 shares of Series A convertible preferred stock outstanding, providing a total of 20,222,027 votes. Holders representing 18,307,120 votes, or approximately 90.53% of the voting power, were present or represented by proxy.
Stockholders elected three Class III directors to terms ending in 2029, with each nominee receiving over 13.3 million votes for and about 1.8–1.9 million votes withheld. They ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026 with 18,245,337 votes for. On an advisory basis, stockholders approved executive compensation with 13,671,195 votes for and selected one year as the preferred frequency for future say-on-pay votes, supported by 14,814,363 votes. The board determined the company will hold advisory votes on named executive officer compensation every year until the next required frequency vote or a different frequency is later determined.
LENSAR, Inc. appointed Michael A. Rossi as Interim Chief Financial Officer and principal financial officer, effective May 29, 2026. Rossi, 52, has extensive healthcare and life sciences finance experience, including prior CFO roles at Access Vascular, ConcertAI and Harvard Bioscience.
The company entered a consulting agreement with Monomoy Advisors LLC, under which Monomoy makes Rossi available at a cash retainer of $375 per hour. LENSAR also set its 2026 virtual annual meeting for August 4, 2026, with holders of common stock and Series A Convertible Preferred Stock of record as of June 10, 2026 entitled to vote. Stockholder proposal and director nomination notices, including those under universal proxy rules, must be received by the company by the close of business on June 8, 2026.
LENSAR, Inc. reported first quarter 2026 results showing lower revenue but a sharp swing to reported profitability driven by one‑time items. Total revenue was $13.4 million, down 5% from $14.2 million a year earlier, mainly from a $1.8 million decline in system sales partly offset by higher procedure revenue.
Recurring revenue grew 9% to $12.6 million and represented 94% of total revenue, supported by 54,094 procedures and 7 new ALLY System placements, bringing the total installed base to about 440 systems and an ALLY backlog of 11 units. Net income reached $36.3 million, primarily from $10.0 million of acquisition‑related income tied to the terminated merger and $23.9 million of non‑cash income from changes in warrant liabilities, while Adjusted EBITDA was roughly breakeven at a $0.3 million loss. Cash, cash equivalents and investments were $13.5 million as of March 31, 2026.
LENSAR, Inc. announced that Chief Financial Officer Thomas R. Staab, II has notified the company of his intention to resign, effective May 8, 2026. He will continue to serve as the company’s principal financial officer until that transition date. The company states his resignation is not due to any disagreement regarding operations, policies, or practices, and has begun a search for a new Chief Financial Officer.
LENSAR, Inc. reported fourth quarter and full-year 2025 results showing a stronger recurring revenue base and growing adoption of its ALLY Robotic Cataract Laser System. Total revenue was $16.0 million in Q4 2025 and $58.4 million for 2025, up from $53.5 million in 2024, with recurring revenue reaching $46.3 million, or 79% of total for both Q4 and the year.
Q4 system revenue declined as the company placed 15 ALLY systems, but procedure-based revenue rose, with worldwide 2025 procedure volume up 22% to 206,014. The ALLY installed base grew 48% year over year to about 200 systems, and the combined laser installed base reached roughly 435 systems.
Despite higher acquisition-related costs tied to a previously contemplated merger with Alcon, net loss narrowed sharply in Q4 to $1.5 million versus $18.7 million a year earlier, mainly due to changes in warrant liability fair value. For 2025, net loss was $34.3 million. Cash, cash equivalents and investments totaled $18.0 million at December 31, 2025, and the company notes it will retain a $10.0 million merger deposit following termination of the Alcon transaction, while recognizing significant acquisition-related expenses.
LENSAR, Inc. announced that it has terminated its previously agreed merger with Alcon Research, LLC. The parties signed a Termination and Mutual Release Agreement on March 16, 2026, ending the deal and releasing each other from claims related to the merger.
Under the termination terms, LENSAR will retain the $10.0 million deposit that Alcon had provided. LENSAR states it understands the Federal Trade Commission intends to seek to enjoin the acquisition, and that required U.S. regulatory approvals were unlikely before the merger’s outside dates in April or July 2026.
The company says it will continue as an independent medical technology business focused on its ALLY Robotic Cataract Laser System and plans to report fourth quarter and full-year 2025 financial results and a strategic update on March 31, 2026.
LENSAR, Inc. filed an amended report to restate and clarify its disclosure about a new credit facility with Wells Fargo Bank, N.A. The company has entered into a Priority Credit Line Agreement that provides a revolving, non-purpose margin credit line secured by a first-priority lien on a designated brokerage account.
Based on the collateral value in this account, LENSAR may borrow up to $9.2 million. Borrowings accrue interest, at the company’s election, at either a fixed rate based on the Treasury Yield plus a margin over a chosen term, or a variable rate based on SOFR plus a margin. The agreement includes customary events of default tied to missed payments, collateral shortfalls, insolvency proceedings, and related security agreements.
LENSAR, Inc. has entered into a Priority Credit Line Agreement with Wells Fargo Bank, N.A. providing a revolving, non-purpose margin credit facility of up to $50 million, secured by a first-priority lien on a designated brokerage account at Wells Fargo.
Approximately $10 million in collateral has been deposited in this account to support borrowings. The company can choose interest based on either a fixed rate using the Treasury Yield plus a margin, or a variable rate using SOFR plus a margin. The agreement includes customary events of default such as missed payments, failure to post additional collateral, insolvency events, or insufficient collateral value.
LENSAR, Inc. provided an update on its pending acquisition by Alcon Research, LLC. The companies continue to work with U.S. Federal Trade Commission staff following a Request for Additional Information and Documentary Material, known as a Second Request, related to the proposed transaction.
Based on the current regulatory review process, LENSAR now expects the Alcon transaction to close in the first half of 2026, subject to satisfaction of closing conditions, including FTC approval. The company also highlights risks that the deal may be delayed, may not close, could be terminated with a potential termination fee, and that its stock price may decline significantly if the transaction is not completed.
LENSAR, Inc. furnished a press release announcing financial results for the fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The information in this report, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act. The filing also includes Exhibit 104, the cover page interactive data file.
LENSAR, Inc. announced its 2025 annual meeting of stockholders is scheduled for December 18, 2025 and will be held virtually. Stockholders of record as of the close of business on October 24, 2025 may vote.
The meeting will only occur if the proposed merger with Alcon Research, LLC is not completed before that date. If the merger closes earlier, the company will become a wholly owned subsidiary and the meeting, director nominations, and any stockholder proposals will not be considered.
Deadlines: to be included in the proxy under Rule 14a-8, proposals must be received by October 31, 2025. For other bylaw proposals or director nominations, written notice is due by October 31, 2025. Universal proxy Rule 14a-19 notices are also due by October 31, 2025.